Trial Profile
Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Cytarabine; Fludarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms V-FIRST
- 12 Dec 2023 Preliminary results assessing early time-points (TPs) MRD analysis with the aim of identify the most informative TPs for MRD assessment and prognostic correlations, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results assessing safety and efficacy of venetoclax (VEN) in combination with FLAI (fludarabine, cytarabine, and idarubicin as a first-line treatment for newly diagnosed adult patients with ELN 2017 intermediate- or high-risk AML) were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 15 Jun 2023 Results evaluating the actual advantage of the addition of venetoclax to chemotherapy by comparing AML1718 , AML1310 and real world data, presented at the 28th Congress of the European Haematology Association